Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

8-K Summary

Registrant: Coeptis Therapeutics Holdings, Inc. (the request metadata identifies Z Squared Inc.; the filing itself identifies Coeptis Therapeutics Holdings, Inc.)

Report date: March 19, 2024; filed March 25, 2024. The filing was submitted under Item 4.02 regarding non-reliance on previously issued financial statements.

Business Context and Reporting Period

The Audit Committee determined that previously issued financial statements for the year ended December 31, 2022, the quarters ended March 31, June 30, and September 30, 2023, and related financial information included in specified registration statements should no longer be relied upon.

Financial Reporting Matters

  • The company identified an unrecorded liability arising from its October 2022 merger with Bull Horn Holdings Corp. The liability must be recorded on the consolidated balance sheet, requiring a restatement of the affected financial statements.
  • As of March 22, 2024, the merger-related liability had an immaterial remaining balance and was expected to be paid during 2024.
  • The company also identified a reimbursement commitment related to academic research under a January 25, 2023 corporate research agreement. The obligation must be recorded on the balance sheet and in the statements of operations, requiring restatement of the three 2023 quarterly periods.
  • No invoices had been received and no reimbursement payments had been made as of March 22, 2024. Management expects reimbursement requests for the 2023 quarterly periods to be received and paid in the near future.
  • The filing does not provide the dollar amounts of either obligation or the expected effect on revenue, net income, cash flow, margins, assets, liabilities, or equity.

Material Changes Versus Prior Periods

The company concluded that the identified accounting errors affect previously reported periods and require restatement. The filing does not quantify the restatement adjustments or provide revised financial metrics.

Controls, Outlook, and Risks

  • The company expects to file the applicable restated financial statements as soon as practicable.
  • Management previously disclosed weaknesses in disclosure controls and procedures during the relevant periods. In 2023, the company hired a full-time Chief Financial Officer, which management believes has improved and will continue to improve control processes.
  • Key risks include delays in completing the restatements, additional audit and review requirements, costs and diversion of personnel, potential litigation or regulatory action, failure to remediate material weaknesses, reputational harm, effects on the common stock, and possible adverse conclusions by the independent auditor.
  • The filing was provided to the company’s independent auditor, Turner, Stone & Company, L.L.P., before submission.

Investor Verification Items

  • Verify the filing of the corrected 2022 and 2023 financial statements and the timing of any required interim reviews or audits.
  • Verify the quantified impact of both identified obligations on liabilities, expenses, net loss, cash flow, and stockholders’ equity.
  • Assess whether the company identifies material weaknesses in internal control over financial reporting and whether remediation is effective.
  • Monitor any auditor, SEC, litigation, or regulatory developments related to the restatement.
  • Evaluate the company’s liquidity and ability to fund the expected reimbursement payments; the filing does not provide current liquidity or debt metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.